1stOncology™: Cancer Intelligence Service – Page 11287 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting

On May 15, 2020 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported presentations related to its AUTO1 and AUTO3 programs, the company’s CAR T cell therapies being investigated in Phase 1/2 studies of adult Acute Lymphocytic Leukemia (ALL) and relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL), respectively, at the European Hematology Association (EHA) (Free EHA Whitepaper) EHA (Free EHA Whitepaper)25 Virtual Congress on June 11 – 14, 2020 (Press release, Autolus, MAY 15, 2020, View Source [SID1234558177]). The AUTO1 data to be presented will expand on the positive data presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) in December 2019 with additional patients as well as longer term data on previously treated patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Oral Presentation Title: ALLCAR19: Updated data using AUTO1, a novel fast-off rate CD 19 CAR in relapsed/refractory B-Acute Lymphoblastic Leukaemia
Session Title: Cellular, antibody and targeted therapy
Abstract: S119
Date/Time: All oral abstract presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.
Presenter: Dr. Claire Roddie MD, PhD, FRCPath, Consultant Haematologist and Honorary Senior Lecturer, Cancer Institute, University College London (UCL)

Oral Presentation Title: Phase 1 Alexander Study of AUTO3 the first Bicistronic Chimeric Antigen Receptor (CAR) targeting CD19 and CD22 with Pembrolizumab in patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Session Title: Aggressive Lymphomas: Cellular and bispecific antibody therapies
Abstract: S240
Date/Time: All oral abstract presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020
Presenter: Dr Wendy Osborne, MBBS (Hons) MRCP FRCPath, Consultant Haematologist, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust

Investor call on Monday June 15, 2020
Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the EHA (Free EHA Whitepaper) data. To listen to the webcast and view the accompanying slide presentation, please go to: View Source

The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID 4838626. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID 4838626.

BioLineRx to Report First Quarter 2020 Results on May 20, 2020

On May 15, 2020 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, reported it will release its unaudited financial results for the quarter ended March 31, 2020 on Wednesday, May 20, 2020, before the US markets open (Press release, BioLineRx, MAY 15, 2020, View Source [SID1234558176]).

The Company will host a conference call on Wednesday, May 20, 2020 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

To dial into the conference call, please dial +1-888-668-9141 from the U.S. or +972-3-918-0609 internationally. A replay of the conference call will be available approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until May 22, 2020; please dial +1-888-782-4291 from the U.S. or +972-3-925-5928 internationally.

BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

On May 15, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its investigational anti-PD-L1 antibody BGB-A333 and preclinical data on three early-stage drug candidates will be presented at the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, taking place on June 22-24, 2020 (Press release, BeiGene, MAY 15, 2020, View Source [SID1234558175]).

Poster Presentations:

Title: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors
Abstract #: 9496
Poster Board #: CT253
Session Category: CT01 Phase 1 Adult Clinical Trial
Session Title: Phase 1 Trials in Progress
Lead Author: Jayesh Desai, MBBS, FRACP, Peter MacCallum Center Centre, Australia

Title: BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo
Abstract #: 664
Poster Board #: 11
Session Category: Experimental and Molecular Therapeutics
Session Title: PI3K/AKT/mTOR Inhibitors
Lead Author: Xiao Yang, BeiGene

Title: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models
Abstract #: 3077
Poster Board #: 11
Session Category: Experimental and Molecular Therapeutics
Session Title: Topoisomerases, Tubulin, and Other Small Molecule Therapeutic Agents
Lead Author: Nan Hu, BeiGene

Title: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
Abstract #: 6415
Poster Board #: 9
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Therapeutic Approaches
Lead Author: Xi Yuan, BeiGene

AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference

On May 15, 2020 AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, reported that it will showcase key programs focused on novel targets in neurodegenerative diseases at next week’s UBS Virtual Global Healthcare Conference (May 18–20, 2020) (Press release, AC Immune, MAY 15, 2020, View Source [SID1234558174]).

Speaking on May 20th, Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA, will outline the cutting-edge science behind AC Immune’s therapeutic and diagnostic programs in TDP-43 and alpha-synuclein – which are amongst the most comprehensive in the field. Both targets are considered to be major pathologies in neurodegenerative diseases, and increasingly thought to be important co-pathologies in Alzheimer’s disease and Parkinson’s disease. This highlights the need for the precision medicine approach pioneered by AC Immune to achieve earlier and more accurate diagnosis.

In addition to the Company’s TDP-43 and alpha-synuclein targeting programs, the presentation will also detail advances for the clinical stage assets addressing the well-established pathophysiology mediated by Tau and Abeta. The critical role of the Company’s two proprietary platforms, SupraAntigen and Morphomer, in fueling advances for antibodies and small molecules, respectively, will also be highlighted.

UBS Virtual Global Healthcare Conference
Date: May 20, 2020 | 9:10–10:00 am ET/ 3:10–4:00 pm CET
Format: Virtual presentation
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune SA

A webcast of the presentation will be available on the Events Page of AC Immune’s website.

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

On May 15, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that data from two studies investigating innate cell engagers developed from its fit-for-purpose ROCK platform have been accepted for e-poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II being held on June 22-24, 2020 (Press release, Affimed, MAY 15, 2020, View Source [SID1234558173]). Affimed researchers served as authors on abstract #5659 and co-authors on abstract #6987 with scientific collaborators from Genentech, a member of the Roche Group, on the respective abstracts that include the following:

Title: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies

Abstract: 5659

Authors: Uwe Reusch, Michael Damrat, Susanne Wingert, Stefan H.J. Knackmuss, Thomas Mueller, Ivica Fucek, Ute Schniegler-Mattox, Kristina Ellwanger, Torsten Haneke, Andras Strassz, Wolfgang Fischer, Erich Rajkovic, Michael Tesar. Affimed GmbH, Heidelberg, Germany

Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.

Title: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma

Abstract: 6987

Authors: Satoko Kakiuchi-Kiyota, Melissa Schutten, Adeyemi O. Adedeji, Hao Cai, Robert Hendricks, Luna Liu, Sivan Cohen, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida-Nagata, Shelly Zhong, Michael Dillon, Christoph Spiess, Steve Leong, Bing Zheng. Genentech Inc.; Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Thorsten Ross. Affimed; Andy Polson, Ayse Meric Ovacik. Genentech Inc.

Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.

More details about the programs for the AACR (Free AACR Whitepaper) Virtual Annual Meeting II are available online at www.aacr.org.

Conference Call Information

Affimed will host a live teleconference today, Friday May 15th at 8am Eastern to discuss the abstracts and recent corporate developments. The teleconference details will be available in the "Webcasts" section on the "Investors" page of the Affimed website at View Source, and a replay of the teleconference will be accessible at the same link for 30 days following the call.